FundedIQ
Biotechnology

Glyscend

Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. The company's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.

www.glyscend.com Baltimore, United States 11-50 employees
Total raised
$20.5M
Rounds
1
Latest
Jun 2020

Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. The company's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.

Glyscend has raised $20.5M across 1 round. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Jun 11, 2020
$20.5M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Glyscend is featured in

Similar companies

AI Metrics

AI Metrics is an early stage company creating transformational image analysis technology that positions radiologists to be the most efficient, valuable clinicians in the patient care continuum

Venture - Series Unknown $950k
Hermes Biosciences

Hermes Biosciences describes a benchtop, hands-off extracellular vesicle isolation system designed to purify exosomes quickly, efficiently.

Seed $6.0M
Bambusa Therapeutics

Bambusa Therapeutics is a biotechnology company that specializes in the development of bispecific antibodies.

Series A
Solarea Bio

Solarea Bio is a biotech company focused on developing microbial therapeutics to treat chronic inflammatory conditions and improve human health. They specialize in researching and creating natural-based therapeutics to address chronic inflammation, providing hospitals with effective medicinal options. By studying genomic sequences of microbes found in healthy foods, Solarea is able to create combinations of bacteria, fungi, and prebiotic fibers that have strong anti-inflammatory properties to target specific chronic illnesses. Their research has been tested in lab and animal studies, with their first application designed to help manage metabolic processes that lead to osteopenia and osteoporosis in postmenopausal women. Founded in 2017 in Cambridge, Massachusetts by Eric Schott, Gerardo Toledo, and Jillian DeWalt, Solarea Bio offers a natural solution to improve women's health and well-being.

Venture - Series Unknown $9.9M
Eclipse Bioinnovations

Eclipse Bioinnovations is a leading RNA genomics company founded in 2017 based on technology developed at the University of California, San Diego. Eclipse's mission is to use their pioneering RNA genomics platform technologies to advance RNA medicines and scientific discovery. Eclipse’s founders developed eCLIP, the world’s most efficient and unique CLIP-seq technology for identifying RNA binding protein gene partners and gene maps. Eclipse’s suite of RNA genomics technologies now cover eCLIP-RBP for mapping the RNA binding proteins, miR-eCLIP for the miR-interactome, m6A-eCLIP for RNA modifications, End-Seq for 5' and 3' mapping, and FLI-Seq for simplifying Crispr library prep. Products are offered as services and kit for biopharma companies and academic researchers, and can be customized for clients.

Venture - Series Unknown $4.9M
Aspen Neuroscience

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson’s disease (PD) and extending across the brain and affected organs.

Series C $115M
VST Bio

VST Bio is a biotechnology company that offers and develops treatment for vascular diseases.

Venture - Series Unknown $28.9M
Gate Bioscience

Gate Bioscience is a biotech company that is developing a new type of medicine called Molecular Gates. These drugs are small molecules that selectively remove harmful extracellular proteins from inside the cell, where they originate. There are more than 4,000 extracellular proteins produced by humans, and over 1,000 of them can cause diseases when they function incorrectly. Molecular Gates aim to eliminate these disease-causing proteins, thereby eradicating the associated diseases for patients. The mechanism of action for Molecular Gates is unique, as they bind to a single channel in the cell through which extracellular proteins pass when they are secreted. By creating a "gate" in this channel, the Molecular Gates can block and recognize specific disease-causing proteins, preventing their exit from the cell. Consequently, the harmful proteins are degraded by the cell rather than being secreted. Gate Bioscience's mission to develop Molecular Gate medicines is supported by Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. For more information, visit www.gatebio.com.

Series B $65.0M
Epalex

EpaleX is developing a novel inhaled treatment for epilepsy and migraine. The treatment for the first time provides a way for patients with epilepsy to gain control over their seizures. When a seizure warning sign (aura) occurs, the patient will be able to prevent the development of a full-blown seizure through the use of a pocket nebulizer to deliver a powerful antiseizure medication that rapidly enters the brain and stops the seizure. The effect of the drug dissipates within minutes, allowing the patient to resume normal daily activity. The inhaler is also used to stop migraine attacks that are refractory to currently available migraine treatments.

Venture - Series Unknown $1.2M
iQure Pharma

iQure Pharma is a biotechnology company founded by entrepreneurs and ex-pharmaceutical executives that specializes in creating innovative treatments on a global scale.

Venture - Series Unknown $1.5M
Clever Carnivore

Clever Carnivore is cell-cultured meat startup that uses stem cell biology, recombinant protein, and bioengineering to create cost-effective lab grown meats. With the company's high-efficiency model, cruelty-free, environmentally friendly, and cost-competitive technology it aims to produce sausage, burgers, and chicken nuggets.

Seed $2.4M
The EVERY Company

The EVERY Company is the market leader in engineering, manufacturing and formulating animal-free, animal proteins as ingredients for the global food and beverage industry. Leveraging advanced fermentation to produce functional and nutritional proteins from microorganisms, the Company is reimagining the factory farm model that underpins industrial animal agriculture with a more sustainable, kinder, and healthier alternative. Clara Foods is on a mission to decouple the world's most powerful proteins from the animals that make them.

Series D $55.0M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.